Ypsomed Holding AG develops, manufactures, and sells injection pens for pharmaceutical and biotech companies worldwide. The company operates in two segments, Delivery Devices and Diabetes Direct Business. The Delivery Devices segment products include pen systems, pen needles, infusion sets, and other injection moldings products. The Diabetes Direct Business sells and trades devices for the self-monitoring of blood glucose levels, as well as infusion pumps, accessories, and other day-to-day items for diabetics. It offers insulin pumps, injection systems, and pen needles for the treatment of diabetes, growth disorders, infertility, and other therapeutic areas; and pen needles under the mylife Diabetescare brand for the treatment of diabetes. Ypsomed Holding AG markets its products through biotech and pharmaceutical partners, as well as through its own distribution network and independent distributors. The company was founded in 1984 and is headquartered in Burgdorf, Switzerland.
ypsomed holding ag-reg
(YPSN:SIX Swiss Ex)
Phone: 41 34 424 41 11
Fax: 41 34 424 41 22www.ypsomed.com
|Antares Pharma Inc||$2.33 USD||+0.06|
|Becton Dickinson and Co||$139.89 USD||-0.93|
|Terumo Corp||¥2,906 JPY||+15.00|
|Unilife Corp||$4.32 USD||+0.04|
|West Pharmaceutical Services Inc||$49.85 USD||+0.04|
|View Industry Companies|
Sponsored Financial Commentaries
To contact YPSOMED HOLDING AG-REG, please visit www.ypsomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.